Company intelligence / Profile preview

Guangzhou Henovcom Bioscience Co., Ltd.

Guangzhou, Guangdong, Chinaen.henovcom.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Henovcom has multiple new molecular entities in clinical development targeting unmet needs such as antiviral, anti-fibrotic, inflammation, and CNS disorders. Its lead program HNC364—a long acting injectable prodrug of rasagiline for Parkinson’s—has completed Phase I trials in the US. The company also develops innovative mRNA capping technologies used globally for research and commercial applications. Several assets are advancing through IND-enabling studies or early clinical phases in both China and the US.[1][2][9]

Therapeutic areas: OncologyPulmonologyNeurologyInfectious Diseases
Modalities: Small moleculesmRNA therapeutics and vaccinesProdrugsModified nucleotides/capping agents for mRNA synthesis[1][2][7]
Industry: Biotech

Drug pipeline

6 assets

HNC1058

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Guangzhou Henovcom Bioscience Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Henovcom Bioscience Co., Ltd..

Explore the full profile